Lynx1 Capital Management LP Stoke Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $338 Million
- Q2 2025
A detailed history of Lynx1 Capital Management LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,404,674 shares of STOK stock, worth $73.1 Million. This represents 18.16% of its overall portfolio holdings.
Number of Shares
5,404,674
Previous 5,291,929
2.13%
Holding current value
$73.1 Million
Previous $35.2 Million
74.31%
% of portfolio
18.16%
Previous 13.01%
Shares
7 transactions
Others Institutions Holding STOK
# of Institutions
139Shares Held
57.6MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$73.2 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$69.3 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$62.7 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$59.2 Million6.04% of portfolio
-
Morgan Stanley New York, NY3.57MShares$48.4 Million0.0% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $533M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...